Fourth Hospital of Hebei Medical University Tumor Hospital of Hebei Province
Welcome,         Profile    Billing    Logout  
 0 Trials 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Zhang, Ruixing
NCT03236636: The Phase III Study of Icaritin Versus HUACHANSU PIAN in Hepatocellular Carcinoma Subjects

Recruiting
3
312
RoW
Icaritin, SNG-162, HUACHANSU PIAN, HUACHANSU PIAN（999）
Beijing Shenogen Biomedical Co., Ltd, Chinese Academy of Medical Sciences, NanJing PLA 81 Hospital, Peking University Cancer Hospital & Institute, Beijing Hospital, Guang'anmen Hospital of China Academy of Chinese Medical Sciences, Jinan Central Hospital, Linyi Tumour Hospital, The First Affiliated Hospital of Anhui Medical University, Anhui Provincial Hospital, The First Affiliated Hospital with Nanjing Medical University, The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China, Nanfang Hospital of Southern Medical University, First People's Hospital of Foshan, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Hebei Medical University Fourth Hospital, The First Hospital of Jilin University, Haikou People's Hospital, Fudan University, West China Hospital, Chongqing Traditional Chinese Medicine Hospital, Chifeng Municipal Hospital, The Affiliated Hospital of Hangzhou Normal University, The First Affiliated Hospital of Zhengzhou University, Guilin Medical University, China, The Third Xiangya Hospital of Central South University, Yunnan Provincial Hospital of Traditional Chinese Medicine, The Sixth People's Hospital of Shenyang
Advanced HBV-Related Hepatocellular Carcinoma (HCC)
12/22
12/22
HERIZON-GEA-01, NCT05152147 / 2021-000296-36: A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

Active, not recruiting
3
920
Europe, Canada, Japan, RoW
Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil
Jazz Pharmaceuticals, BeiGene
Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma
05/25
05/26
ALTER-C003, NCT04970914: Anlotinib Plus Penpulimab (AK105) for Chemo-refractory Metastatic Colorectal Cancer:

Recruiting
2
32
RoW
Anlotinib, anlotinib hydrochloride, Penpulimab, AK105
Peking Union Medical College Hospital
Colorectal Cancer
08/22
08/23
NCT05247216: A Phase 2 Study of Hemay007 in Patients With Rheumatoid Arthritis

Completed
2
140
RoW
Hemay007 800 mg QD group, Hemay007 1200 mg QD group, Hemay007 600 mg QD group, Hemay007 placebo group
Tianjin Hemay Pharmaceutical Co., Ltd
Rheumatoid Arthritis
06/23
06/23
NCT04718402: A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Advanced Gastric Carcinoma

Terminated
1
21
RoW
Mitoxantrone Hydrochloride Liposome, intravenous injection
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Advanced Gastric Carcinoma
05/22
05/22
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Zhang, Ruixing
NCT03236636: The Phase III Study of Icaritin Versus HUACHANSU PIAN in Hepatocellular Carcinoma Subjects

Recruiting
3
312
RoW
Icaritin, SNG-162, HUACHANSU PIAN, HUACHANSU PIAN（999）
Beijing Shenogen Biomedical Co., Ltd, Chinese Academy of Medical Sciences, NanJing PLA 81 Hospital, Peking University Cancer Hospital & Institute, Beijing Hospital, Guang'anmen Hospital of China Academy of Chinese Medical Sciences, Jinan Central Hospital, Linyi Tumour Hospital, The First Affiliated Hospital of Anhui Medical University, Anhui Provincial Hospital, The First Affiliated Hospital with Nanjing Medical University, The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China, Nanfang Hospital of Southern Medical University, First People's Hospital of Foshan, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Hebei Medical University Fourth Hospital, The First Hospital of Jilin University, Haikou People's Hospital, Fudan University, West China Hospital, Chongqing Traditional Chinese Medicine Hospital, Chifeng Municipal Hospital, The Affiliated Hospital of Hangzhou Normal University, The First Affiliated Hospital of Zhengzhou University, Guilin Medical University, China, The Third Xiangya Hospital of Central South University, Yunnan Provincial Hospital of Traditional Chinese Medicine, The Sixth People's Hospital of Shenyang
Advanced HBV-Related Hepatocellular Carcinoma (HCC)
12/22
12/22
HERIZON-GEA-01, NCT05152147 / 2021-000296-36: A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

Active, not recruiting
3
920
Europe, Canada, Japan, RoW
Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil
Jazz Pharmaceuticals, BeiGene
Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma
05/25
05/26
ALTER-C003, NCT04970914: Anlotinib Plus Penpulimab (AK105) for Chemo-refractory Metastatic Colorectal Cancer:

Recruiting
2
32
RoW
Anlotinib, anlotinib hydrochloride, Penpulimab, AK105
Peking Union Medical College Hospital
Colorectal Cancer
08/22
08/23
NCT05247216: A Phase 2 Study of Hemay007 in Patients With Rheumatoid Arthritis

Completed
2
140
RoW
Hemay007 800 mg QD group, Hemay007 1200 mg QD group, Hemay007 600 mg QD group, Hemay007 placebo group
Tianjin Hemay Pharmaceutical Co., Ltd
Rheumatoid Arthritis
06/23
06/23
NCT04718402: A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Advanced Gastric Carcinoma

Terminated
1
21
RoW
Mitoxantrone Hydrochloride Liposome, intravenous injection
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Advanced Gastric Carcinoma
05/22
05/22

Download Options